###begin article-title 0
Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 528 529 528 529 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 565 566 565 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 492 497 <span type="species:ncbi:9606">human</span>
###xml 608 612 <span type="species:ncbi:10090">mice</span>
We have shown previously that treatment with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) reduced the expression of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor type 2 (VEGFR2) and growth of 4T1-breast cancer (BC) in syngeneic mice. In this investigation, PEG-LPrA2 was used to evaluate whether the inhibition of leptin signaling has differential impact on the expression of pro-angiogenic and pro-proliferative molecules and growth of human estrogen receptor-positive (ER+) and estrogen receptor-negative (ER-) BC xenografts hosted by immunodeficient mice.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 188 190 188 190 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 254 256 254 256 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 341 343 341 343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 349 351 349 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 161 165 <span type="species:ncbi:10090">mice</span>
To test the contribution of leptin signaling to BC growth and expression of leptin-targeted molecules, PEG-LPrA2 treatment was applied to severe immunodeficient mice hosting established ER+ (MCF-7 cells; ovariectomized/supplemented with estradiol) and ER- (MDA-MB231 cells) BC xenografts. To further assess leptin and PEG-LPrA2 effects on ER+ and ER- BC, the expression of VEGF and VEGFR2 (protein and mRNA) was investigated in cell cultures.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 51 53 51 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 71 73 71 73 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 268 269 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 276 278 276 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 288 290 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 318 320 318 320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 294 299 <span type="species:ncbi:10090">Mouse</span>
PEG-LPrA2 more effectively reduced the growth of ER+ (>40-fold) than ER- BC (twofold) and expression of pro-angiogenic (VEGF/VEGFR2, leptin/leptin receptor OB-R, and IL-1 receptor type I) and pro-proliferative molecules (proliferating cell nuclear antigen and cyclin D1) in ER+ than in ER- BC. Mouse tumor stroma in ER+ BC expressed high levels of VEGF and leptin that was induced by leptin signaling. Leptin upregulated the transcriptional expression of VEGF/VEGFR2 in MCF-7 and MDA-MB231 cells.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 92 94 92 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 100 102 100 102 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 309 311 309 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 317 319 317 319 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
These results suggest that leptin signaling plays an important role in the growth of both ER+ and ER- BC that is associated with the leptin regulation of pro-angiogenic and pro-proliferative molecules. These data provide support for the potential use of leptin-signaling inhibition as a novel treatment for ER+ and ER- BC.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob </italic>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 368 369 368 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 492 493 492 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 664 665 664 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
Leptin is a small nonglycosylated protein (16 kDa) product of the ob gene. White adipose tissue is the primary source of leptin in benign tissue, but leptin is also expressed and secreted by cancer cells [1]. Leptin exclusively binds to its receptor, OB-R. Several isoforms of OB-R are found in diverse tissues and in cancer cells including the long isoform, OB-Rb [2,3]. Upon leptin activation, the OB-R isoforms can utilize a number of diverse signaling pathways relevant to cancer growth [4,5]. The well-documented biological actions of leptin at the hypothalamic level occur through OB-Rb signals that are linked to the control of appetite and energy balance [4].
###end p 11
###begin p 12
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 133 134 133 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 324 326 324 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 452 453 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 617 619 617 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 714 716 714 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 591 596 <span type="species:ncbi:9606">women</span>
Evidence is mounting to support the idea that leptin is the link between obesity and the higher incidence of a variety of cancers [6,7]. Several studies show that conditions characterized by high levels of leptin (female gender, obesity, menopause) are positively correlated with a higher incidence of breast cancer (BC) [8-10]. For BC patients, obesity can be an indicator of a poor prognosis even after the administration of adjuvant chemotherapy [6,7]. Nevertheless, there are contradicting reports showing no association between serum levels of leptin in premenopausal or postmenopausal women and the risk of BC [11,12]. Leptin and OB-R levels, however, are higher in BC cells than in normal mammary cells [13,14].
###end p 12
###begin p 13
###xml 659 661 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 771 773 767 769 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 825 827 821 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 828 830 824 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 943 945 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1136 1138 1132 1134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1139 1141 1135 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1282 1283 1278 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 1428 1430 1424 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1126 1134 <span type="species:ncbi:9606">patients</span>
Almost all BC cells can develop metastases. This depends on the intricate relations of numerous tumor cell factors that include location and extension of cancer, the type and differentiation of the tumor cells, as well as other only incompletely understood factors. A role for the mammary fat pad in mammary gland development and enhancement of the growth and ability to metastasize BC cells has been described. Cytokines, the tumor microenvironment, adipose tissue, and the tissue microenvironment in remote organs could contribute to prime BC cells, promoting metastasis. Among these factors, TNFalpha and IL-1 are potent leptin inducers in adipose tissue [15]. The majority of BC cells express estrogen receptor (ER) and their growth is mainly driven by ER signaling [16] that could also be activated by leptin signaling [17-19]. A high level of OB-R in BC is a significant risk factor, independent of ER expression and other risk factors [13]. Moreover, there is significant correlation between the levels of leptin/OB-R in BC and a higher incidence of BC metastatic disease, poor prognosis, and lower survival rate of BC patients [13,14]. Leptin signaling could play an important role in the growth of highly invasive, metastatic, and more deadly estrogen receptor-negative (ER-) BC cells that do not respond to endocrine therapy and are mostly treated with chemotherapeutics that exhibit several detrimental side effects [20].
###end p 13
###begin p 14
###xml 235 237 235 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 317 319 317 319 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 341 343 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 393 395 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 427 428 427 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 583 585 583 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 322 327 <span type="species:ncbi:9606">human</span>
###xml 378 383 <span type="species:ncbi:10090">mouse</span>
Leptin's pleiotropic effects are linked to diverse processes that if de-regulated could contribute to the growth of cancer; that is, proliferation, anti-apoptosis, angiogenesis, extracellular membrane component changes and metastasis [21-24]. Leptin enhances the expression of cell cycle regulators cdk-2 and cyclin D1 in human BC cells [22,23] and of pro-angiogenic factors in mouse mammary [24] and endometrial cancer cells [3]. Furthermore, leptin signaling is related with an increase cell survival since it can upregulate the expression of the anti-apoptotic protein, Bcl-2 [25-27]. Leptin's pleiotropic actions may therefore impact the growth of cancer through a variety of mechanisms. Hence, leptin may play an important role in controlling the proliferation, survival, and migration of cells involved in cancer growth. A recent published study by Perera and colleagues has reinforced this idea, showing data supporting leptin promotion of mammary tumor (MT) growth through multiple mechanisms, including regulating the cell cycle, apoptosis, and modulating the extracellular environment [28]. Little is known, however, about the exact mechanism(s) by which leptin contributes to tumor progression.
###end p 14
###begin p 15
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 217 223 217 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ob/ob </italic>
###xml 227 232 227 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">db/db</italic>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 442 444 442 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 543 545 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 175 179 <span type="species:ncbi:10090">mice</span>
###xml 336 361 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 362 367 <span type="species:ncbi:9606">human</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 870 875 <span type="species:ncbi:9606">human</span>
Data from animal studies reinforced the idea that leptin can contribute to BC growth. Obese rodents have a higher incidence of MTs than lean controls [29]. In contrast, obese mice with deficiency of leptin-signaling (ob/ob and db/db) have a significantly lower incidence of MT than their lean littermates [30,31]. Furthermore, nonobese mouse mammary tumor virus/human transforming growth factor-alpha mice have a high rate of MT development [29], which is offset in the offspring when they are crossed with leptin-signaling-deficient mice [30,31]. We previously reported that the blockade of leptin actions in mice hosting syngeneic MTs delayed tumor onset and reduced tumor growth [24]. Well known, however, is the fact that BC has diverse genetic and phenotypic heterogeneity. No single animal model can therefore fully represent all of the possible pathways by which human BC develops or progress.
###end p 15
###begin p 16
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 457 459 457 459 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 482 484 482 484 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 575 577 575 577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 583 585 583 585 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 608 610 608 610 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1086 1088 1086 1088 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1094 1096 1094 1096 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 104 109 <span type="species:ncbi:9606">human</span>
###xml 405 410 <span type="species:ncbi:9606">human</span>
###xml 585 590 <span type="species:ncbi:9606">human</span>
The aim of the present study was to evaluate the impact of leptin-signaling inhibition on the growth of human BC xenografts and their expression of leptin-targeted molecules. Based on the reported leptin-mediated overexpression of aromatase [18] and transactivation of ER [19] in MCF-7 cells, we hypothesized that the effects of pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) on the growth of human BC xenografts will be more evident in MCF-7 ER+ BC than in MDA-MB231 ER- BC. This study shows that leptin signaling plays an important role in the growth of both ER+ and ER- human BC xenografts; ER+ BC cells, however, were more responsive to PEG-LPrA2 treatment. Leptin signaling regulates the expression of angiogenic and pro-proliferative factors in BC and tumor stroma. The leptin tumor-promoting effects are probably direct (cell proliferation and survival) and indirect via the regulation of molecules involved in tumor growth. Collectively, these results strongly suggest that inhibition of leptin signaling may have potential novel therapeutic value for controlling ER+ and ER- BC growth.
###end p 16
###begin title 17
Materials and methods
###end title 17
###begin title 18
Antibodies and reagents
###end title 18
###begin p 19
###xml 168 170 168 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 182 187 <span type="species:ncbi:9606">human</span>
###xml 323 328 <span type="species:ncbi:9606">human</span>
###xml 511 517 <span type="species:ncbi:9986">rabbit</span>
###xml 518 522 <span type="species:ncbi:9925">goat</span>
###xml 789 795 <span type="species:ncbi:9913">bovine</span>
Antibodies for human vascular endothelial growth factor (VEGF) (A-20), for vascular endothelial growth factor receptor type 2 (VEGFR2) (Flk-1 or KDR; A-3), for cyclin D1 (HD11), for human IL-1 receptor type I (IL-1R tI) (N-20, proliferating cell nuclear antigen (PCNA); FL-261), for ERalpha (MC-20), for leptin (Y-20), for human OB-Rb (long isoform intracellular COOH end; C-20) and for cytokeratin 8/18 (0.N.352), blocking peptide antibody for competition studies, positive controls, protein G-agarose and the rabbit/goat ABC staining kit were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). beta-Actin antibody (ab8226) was purchased from Abcam Inc. (Cambridge, MA, USA). RPMI-1640 medium was obtained from American Type Culture Collection (Manassas, VA, USA). Fetal bovine serum was obtained from Gemini Bioproducts (Woodland, CA, USA), and antibiotic-antimycotic mixtures were purchased from Gibco BRL Products (Gaithersburg, MD, USA). Succinimidyl propionate polyethylene glycol (20 kDa) was obtained from Nektar Therapeutics (Huntsville, AL, USA). Other chemicals were obtained from Sigma Inc. (St Louis, MO, USA).
###end p 19
###begin title 20
Leptin peptide receptor antagonist
###end title 20
###begin p 21
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
Leptin receptor antagonist 2 and a scrambled peptide for control were synthesized and purified as described elsewhere [32]. To increase their bioavailability, the peptides were covalently bound to succinimidyl propionate polyethylene glycol (20 kDa; half-life > 60 hours) at 5:1 molecular ratios (leptin receptor antagonist 2:polyethylene glycol) in PBS (pH 7.0), following the manufacturer's instructions (Nektar Therapeutics). In contrast to unconjugated leptin receptor antagonist peptides, their polyethylene glycol derivatives are water-soluble.
###end p 21
###begin title 22
Cell culture
###end title 22
###begin p 23
###xml 48 49 48 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 68 69 68 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 129 131 129 131 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 699 701 698 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 381 387 <span type="species:ncbi:9913">bovine</span>
The human BC adenocarcinoma cell lines MCF-7 (ER+) and MDA-MB231 (ER-) (American Type Culture Collection) were cultured (1.5 x 105 cells/well; duplicate wells; experiments repeated, n = 3) on uncoated flat-bottomed plastic 12-well plates with complete growth medium (American Type Culture Collection). Semi-confluent cells were cultured for 48 hours in basal medium (without fetal bovine serum) containing leptin (0, 0.6, 1.2 and 6.25 nM, equivalent to 0, 10, 20, and 100 ng/ml) and/or PEG-LPrA2 and inert control, pegylated scrambled peptide (Sc-PEG) (5 mM dissolved in water; final concentration in the medium, 3 muM). Conditioned media were harvested and cells were lysed as described elsewhere [24]. Protein concentrations were determined by the Bio-Rad kit (Bio-Rad Lab., Hercules, CA, USA).
###end p 23
###begin title 24
Real-time RT-PCR
###end title 24
###begin p 25
###xml 465 467 465 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R </italic>
Total RNA was extracted, purified from cells (RNeasy and RNase-Free DNase Set; Qiagen Inc., Valencia, CA, USA) and quantified (Quanti-iT RNA Assay Kit/Qubit fluorometer; Invitrogen, Carlsbad, CA, USA). cDNA was synthesized using the iScript cDNA kit (Bio-Rad) and a control without RT was used for each reaction to exclude chromosomal DNA contamination. cDNA samples were analyzed by real-time PCR using IQ SYBR Green Supermix (Bio-Rad). Relative expression values R were calculated using 18S rRNA as reference (n = 3):
###end p 25
###begin p 26

###end p 26
###begin p 27
###xml 29 34 <span type="species:ncbi:9606">human</span>
The sequences of primers for human VEGF mRNA (180 bp DNA fragment), VEGFR2 (Flk1) mRNA (114 bp fragment) and 18S rRNA (317 bp DNA fragment) are available upon request. The PCR conditions were as follows: one cycle, 95degreesC for 3 minutes; and 45 cycles, 95degreesC for 30 seconds, 52degreesC for 30 seconds and 72degreesC for 30 seconds.
###end p 27
###begin title 28
###xml 25 29 <span type="species:ncbi:10090">mice</span>
Therapeutic treatment to mice hosting established breast cancer xenografts
###end title 28
###begin p 29
###xml 437 439 434 436 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 538 540 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 270 274 <span type="species:ncbi:10090">mice</span>
###xml 480 484 <span type="species:ncbi:10090">mice</span>
###xml 526 530 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
All animal studies were approved by the Morehouse School of Medicine Institutional Review Board. Ovariectomized and nonovariectomized NOD.CB17-Prkdcscid/NCrCrl (SCID) mice, 6 weeks old, were obtained from Charles River Laboratories (Wilmington, MA, USA). Ovariectomized mice were subcutaneously implanted with an estradiol capsule (2 mg 17beta-estradiol and 1.6 mg cholesterol) that was replaced every 21 days to sustain the growth of ER+ BC cells. MCF-7 cells for ovariectomized mice or MDA-MB231 cells for nonovariectomized mice (2 x 106 cells/matrigel 4 mg/ml) were orthotopically inoculated into the mammary fat pads of mice (second row, right nipple). The tumor take rate was 100% in all experiments.
###end p 29
###begin p 30
###xml 185 187 185 187 <sup xmlns:xlink="http://www.w3.org/1999/xlink">3 </sup>
###xml 225 227 224 226 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 268 270 267 269 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 289 291 288 290 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 935 937 932 934 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 37 41 <span type="species:ncbi:10090">mice</span>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 836 840 <span type="species:ncbi:10090">mice</span>
Before treatment, the ovariectomized mice hosting MCF-7 BC were slightly heavier than those nonovariectomized mice hosting MDA-MB231. Once tumors reached an approximate volume of 100 mm3 (measured with a caliper; pi/6 x width2 x length), 10 mice/group hosting MCF-7 ER+ BC and MDA-MB231 ER- BC were randomly allocated to two groups per tumor type such that their tumor size and body weight were similar. The mice were then treated with PEG-LPrA2 for leptin-signaling inhibition or with inert Sc-PEG for controls, both 50 mul/0.5 mM in PBS every 48 hours, given by intravenous injection. Because the PEG-LPrA2 half-life is about 60 hours, this schedule will ensure a continuous plasma level of the antagonist. Treatments ended after 18 days. After 8 hours of fasting and before euthanasia, blood was drawn from the retro-orbital vein of mice (mild anesthesia; 400 mul avertin, 200 mg/kg body weight) for VEGF and leptin determinations [24].
###end p 30
###begin title 31
Mammary tumor growth
###end title 31
###begin p 32
Changes in MT size were determined by caliper measurements on a weekly basis. Tumors were dissected and weighed after euthanasia. The impact of treatment on general health, body weight, and food intake was recorded weekly. Carcass weight was determined post mortem.
###end p 32
###begin title 33
Leptin targets in mammary tumors
###end title 33
###begin title 34
Immunoprecipitation/western blot
###end title 34
###begin p 35
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 735 737 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 738 740 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 741 743 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 535 540 <span type="species:ncbi:10090">mouse</span>
###xml 542 548 <span type="species:ncbi:9986">rabbit</span>
###xml 554 558 <span type="species:ncbi:9925">goat</span>
The levels of VEGF, VEGFR2, OB-Rb, cyclin D1, and PCNA in tumor lysates were determined by immunoprecipitation/western blot. Briefly, protein concentrations in lysates from cell cultures and MTs were determined by the Bradford method (Bio-Rad). Thirty micrograms of protein were analyzed by western blot either directly or after immunoprecipitation with protein A or protein G-agarose beads following the manufacturer's instructions (Pierce, Rockford, IL, USA). Antibodies against beta-actin were used as loading controls. Nonspecific mouse, rabbit, and goat IgGs were used as negative controls for western blot analysis. For quantitative evaluation of antigen expression, the blots were scanned and analyzed by the NIH Image program [24,33,34].
###end p 35
###begin title 36
Immunohistochemistry
###end title 36
###begin p 37
###xml 61 69 61 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 174 175 174 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 557 558 544 545 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 559 561 546 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 849 851 836 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 1738 1740 1723 1725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1741 1743 1726 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 600 605 <span type="species:ncbi:9796">horse</span>
###xml 609 615 <span type="species:ncbi:9986">rabbit</span>
To assess the potential effects of blockade of OB-R function in vivo on the expression of various antigens (that is, VEGF, VEGFR2, OB-Rb, leptin, IL-1R tI, PCNA, and cyclin D1), immunohistochemistry in paraffin block sections (4 mum) was performed. Negative controls were also included. Briefly, unmasking of tissue antigens was performed by heat treatment in sodium citrate buffer (pH 6, 10 mM) at 95degreesC for 15 minutes and partial digestion at 37degreesC for 10 minutes with protease (Sigma Inc.). After quenching endogenous peroxidase activity with H2O2 (3% water solution) and blocking (2.5% horse or rabbit normal serum), tissue sections were incubated for 1 hour at room temperature with the following primary antibodies diluted in PBS- 0.1% BSA: anti-VEGF, anti-VEGFR2, anti-OB-Rb, anti-leptin, anti-IL-1R tI, anti-PCNA, and anti-cyclin D1 (all at 1 mug/ml). Monoclonal antibody against cytokeratin 8/18 (dilution 1:100) was routinely used to detect tumor epithelial components. Biotinylated secondary antibodies were used. The tissues were incubated with a streptavidin-biotin-peroxidase system according to the manufacturer's directions (Vectastain, ABC-AP kit; Vector, Burlingame, CA, USA), counterstained with hematoxylin (Dako Corp., Carpinteria, CA, USA), and mounted with VectaMount (Vector). Negative controls included tissue preparations in which the primary antibodies were substituted by irrelevant species-matched IgG. Negative controls for competitive studies with primary antibodies were generated by reincubation with their respective blocking peptides (20 mug/ml; Santa Cruz Biotechnology). All washing steps were performed by immersion of the preparations three times in PBS for 5 minutes at room temperature [24,34].
###end p 37
###begin title 38
Vascular endothelial growth factor and leptin concentrations
###end title 38
###begin p 39
###xml 14 19 <span type="species:ncbi:9606">human</span>
###xml 24 29 <span type="species:ncbi:10090">mouse</span>
###xml 87 92 <span type="species:ncbi:10090">mouse</span>
The levels of human and mouse VEGF and leptin in conditioned media from cell cultures, mouse sera, and MT lysates were determined by ELISA (R&D Systems Inc., Minneapolis, MN, USA).
###end p 39
###begin title 40
Statistical analysis
###end title 40
###begin p 41
###xml 159 161 159 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 175 183 175 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 187 196 187 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 342 344 340 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
A one-way analysis of variance test with Dunnett error protection and confidence interval of 95% was used from the Analyse-it for Microsoft Excel (Leeds, UK) [35] analysis of in vivo and in vitro treatments. The experiments were repeated (n = 3) and all samples were analyzed in duplicate. The data were expressed as mean +/- standard error. P < 0.05 was considered statistically significant. The model included the main effects of treatments and replicates.
###end p 41
###begin title 42
Results
###end title 42
###begin title 43
###xml 2 4 2 4 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
ER+ and ER- breast cancer xenograft growth
###end title 43
###begin p 44
###xml 154 156 154 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 468 470 468 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 659 661 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 812 814 812 814 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1c</xref>
###xml 866 868 866 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1d</xref>
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 420 424 <span type="species:ncbi:10090">mice</span>
###xml 564 568 <span type="species:ncbi:10090">Mice</span>
###xml 799 803 <span type="species:ncbi:10090">mice</span>
###xml 903 907 <span type="species:ncbi:10090">mice</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
Injection of PEG-LPrA2 into mice with established MCF-7 BC xenografts resulted in a dramatic reduction (>40-fold) in the growth of tumor explants (Figure 1a). The reduction of MCF-7 tumors by PEG-LPrA2 was significant after 1 week of treatment. Moreover, at the end of treatment (18 days) the tumors were not palpable, which was confirmed after euthanasia and dissection of the tumor area. This was in contrast to those mice receiving control solution, Sc-PEG (Figure 1b). The treatment with PEG-LPrA2 was also effective in reducing MDA-MB231 BC xenograft growth. Mice hosting established MDA-MB231 BC had a significant reduction of tumor growth rate (Figure 1c). At week 3 of PEG-LPrA2-treatment BC, the volume of MDA-MB231 tumors was decreased approximately twofold when compared with the control mice (Figure 1c), which was assessed by a decrease in mass (Figure 1d). MCF-7 tumor masses from control mice were bigger than those from MDA-MB231 tumors. This could be due to increased vascularization in MCF-7 BC in control mice. The MCF-7 tumors were less differentiated (less prominent nucleoli, less intense chromatin change patterns, non-uniform large cells encountered together with small cells, and so forth) than those from MDA-MB231 BC.
###end p 44
###begin p 45
###xml 109 113 109 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 172 176 172 176 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 223 227 223 227 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 274 278 274 278 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(d) </bold>
###xml 524 525 524 525 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6</sup>
###xml 854 856 853 855 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 911 913 908 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 926 928 923 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 406 411 <span type="species:ncbi:9606">human</span>
###xml 465 469 <span type="species:ncbi:10090">mice</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 723 727 <span type="species:ncbi:10090">mice</span>
###xml 984 988 <span type="species:ncbi:10090">mice</span>
Impact of PEG-LPrA2 treatment on growth of estrogen receptor positive and negative breast cancer xenografts. (a) Growth of established MCF-7 breast cancer (BC) xenografts. (b) Tumor mass of established MCF-7 BC xenografts. (c) Growth of established MDA-MB231 BC xenografts. (d) Tumor mass of established MDA-MB231 BC xenografts. Female SCID mice were orthotopically inoculated into the mammary glands with human estrogen-receptor-positive MCF-7 (for ovariectomized mice) or estrogen-receptor-negative MDA-MB231 cells (2 x 106). The mice were treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) (n = 10/each cell type) or with pegylated scrambled peptide (control; n = 10/each cell type). Ovariectomized mice were supplemented with a subdermal estradiol capsule. Tumor growth was determined using a caliper (tumor volume = pi/6 x width2 x length). Data expressed as mean +/- standard error. *P < 0.05 and **P < 0.01, significant differences with respect to control mice.
###end p 45
###begin title 46
Leptin-targeted molecules in breast cancer xenografts
###end title 46
###begin p 47
###xml 134 136 134 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 262 264 262 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 72 77 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
###xml 182 186 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
Immunohistochemistry analysis revealed that the levels of leptin, OB-R, human VEGF, VEGFR2 or Flk-1, PCNA, human IL-1R tI and cyclin D1 were significantly lower in MCF-7 tumors from mice treated with PEG-LPrA2 than in tumors from Sc-PEG-treated controls (Figure 2a). Similar results were found in MDA-MB231-derived MTs from mice treated with PEG-LPrA2 (Figure 2b). Reduction in the expression of these antigens was more evident, however, in MCF-7 BC than in MDA-MB231 BC (Figure 2).
###end p 47
###begin p 48
###xml 133 137 133 137 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 193 197 193 197 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
###xml 621 625 <span type="species:ncbi:10090">mice</span>
Proliferation, angiogenesis, and inflammation-related molecules in estrogen receptor positive and negative breast cancer xenografts. (a) Estrogen-receptor-positive MCF-7 breast cancer (BC) and (b) estrogen-receptor-negative MDA-MB231 BC from control (pegylated scrambled peptide) and pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2)-treated SCID mice. Pictures show representative results from immunohistochemical analysis of pro-proliferative and pro-angiogenic molecules (n = 5; magnification x100). Arrows indicate stronger staining of the antigens in tumors from controls than tumors from PEG-LPrA2-treated mice. IL-1R tI, interleukin-1 receptor type I; OB-R, leptin receptor; PCNA, proliferating cell nuclear antigen; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor type 2.
###end p 48
###begin p 49
###xml 77 78 77 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 203 205 203 205 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 242 244 242 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3a</xref>
###xml 271 273 271 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3b</xref>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
The impact of PEG-LPrA2 treatment on proliferation markers (PCNA and cyclin D1) was further investigated in tumor lysates by western blot analysis (Figure 3). A significant reduction of PCNA and cyclin D1 levels was found in MCF-7 BC (Figure 3a) and MDA-MB231 BC (Figure 3b) from mice treated with PEG-LPrA2.
###end p 49
###begin p 50
###xml 89 90 89 90 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 92 96 92 96 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 135 139 135 139 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 241 243 241 243 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 460 462 457 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 283 287 <span type="species:ncbi:10090">mice</span>
###xml 496 500 <span type="species:ncbi:10090">mice</span>
###xml 548 552 <span type="species:ncbi:10090">mice</span>
Effects of leptin inhibition on levels of proliferating cell nuclear antigen and cyclin D1. (a) MCF-7 breast cancer (BC) xenograft and (b) MDA-MB231 BC xenograft western blot results for proliferating cell nuclear antigen (PCNA) and cyclin D1 in tumor lysates from controls and SCID mice treated with leptin signaling antagonist (pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2)). beta-Actin was used as a loading control for western blot analysis. *P < 0.05, significant difference in mice treated with PEG-LPrA2 with respect to control mice receiving pegylated scrambled peptide. Data (mean +/- standard error) show representative results (n = 10 tumors/treatment).
###end p 50
###begin title 51
VEGF/VEGFR2 and leptin/OB-Rb in breast cancer xenografts
###end title 51
###begin p 52
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 719 721 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 130 135 <span type="species:ncbi:9606">human</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 294 299 <span type="species:ncbi:10090">mouse</span>
###xml 338 342 <span type="species:ncbi:10090">mice</span>
###xml 384 389 <span type="species:ncbi:9606">human</span>
###xml 419 424 <span type="species:ncbi:10090">mouse</span>
###xml 445 449 <span type="species:ncbi:10090">mice</span>
###xml 536 540 <span type="species:ncbi:10090">mice</span>
PEG-LPrA2 treatment significantly decreased the levels of human VEGF (~15-fold) in MCF-7 BC lysates (Figure 4a). Plasma levels of human VEGF were low and no significant differences were detected between PEG-LPrA2-treated mice hosting MCF-7 BC when compared with controls (Figure 4a). Levels of mouse VEGF in MCF-7 BC lysates from control mice were significantly higher than those for human VEGF. In contrast, levels of mouse VEGF in plasma from mice hosting MCF-7 BC and treated with PEG-LPrA2 were no different from those from control mice (Figure 4a). Immunoprecipitation/western blot analysis showed that VEGF and VEGFR2 levels were significantly reduced by PEG-LPrA2 in MCF-7 BC when compared with controls (Figure 4a).
###end p 52
###begin p 53
###xml 449 452 449 452 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a,c</bold>
###xml 472 475 472 475 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b,d</bold>
###xml 561 563 558 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 576 578 573 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 39 44 <span type="species:ncbi:9606">human</span>
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
###xml 92 96 <span type="species:ncbi:10090">mice</span>
###xml 98 103 <span type="species:ncbi:9606">Human</span>
###xml 108 113 <span type="species:ncbi:10090">mouse</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 181 186 <span type="species:ncbi:10090">mouse</span>
###xml 289 294 <span type="species:ncbi:9606">human</span>
###xml 365 370 <span type="species:ncbi:10090">mouse</span>
###xml 375 380 <span type="species:ncbi:9606">human</span>
###xml 390 395 <span type="species:ncbi:9606">human</span>
###xml 612 616 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
Leptin-inhibition effects on levels of human and mouse VEGF/VEGFR2 and leptin/OB-Rb in SCID mice. Human and mouse vascular endothelial growth factor (hVEGF and mVEGF) and human and mouse leptin (hLeptin and mLeptin) concentrations in tumor lysates and plasma, and western blot results for human VEGF and vascular endothelial growth factor receptor type 2 (VEGFR2) (mouse and human) and for human leptin receptor (OB-Rb) in MCF-7 breast cancer (BC) (a,c) and MDA-MB231 BC (b,d), respectively. beta-Actin was used as a loading control for western blot analysis. *P < 0.05 and **P < 0.01, significant difference in mice treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) with respect to control mice receiving pegylated scrambled peptide, respectively. Data (mean +/- standard error) show representative results (n = 10 tumors/treatment). MT, mammary tumor.
###end p 53
###begin p 54
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 458 460 458 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 557 559 557 559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4b</xref>
###xml 638 640 638 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4a</xref>
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 326 330 <span type="species:ncbi:10090">mice</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:10090">mice</span>
###xml 538 543 <span type="species:ncbi:10090">mouse</span>
###xml 625 629 <span type="species:ncbi:10090">mice</span>
Reduced levels of human VEGF were found in the MDA-MB231 BC from mice treated with PEG-LPrA2 (Figure 4b). Immunoprecipitation/western blot analysis showed that PEG-LPrA2 treatment reduced the levels of VEGFR2 in MDA-MB231 BC (approximately threefold; Figure 4b). In comparison, human VEGF levels in tumor lysates from control mice hosting MDA-MB231 BC xenografts were significantly higher (Figure 4b) than in control mice hosting MCF-7 BC xenografts (Figure 4a). In contrast, stroma in MDA-MB2231 BC from control mice had lower levels of mouse VEGF (Figure 4b) compared with stroma from MCF-7 BC xenografts hosted by control mice (Figure 4a).
###end p 54
###begin p 55
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 273 275 273 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4d</xref>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c</xref>
###xml 875 879 875 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4c,d</xref>
###xml 42 47 <span type="species:ncbi:9606">human</span>
###xml 70 74 <span type="species:ncbi:10090">mice</span>
###xml 141 146 <span type="species:ncbi:10090">mouse</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 338 343 <span type="species:ncbi:9606">human</span>
###xml 402 407 <span type="species:ncbi:10090">mouse</span>
###xml 519 523 <span type="species:ncbi:10090">mice</span>
###xml 551 556 <span type="species:ncbi:9606">human</span>
###xml 584 589 <span type="species:ncbi:10090">mouse</span>
###xml 633 637 <span type="species:ncbi:10090">mice</span>
###xml 753 758 <span type="species:ncbi:9606">human</span>
###xml 816 820 <span type="species:ncbi:10090">mice</span>
PEG-LPrA2 treatment reduced the levels of human leptin in tumors from mice hosting MCF-7 BC xenografts (Figure 4c). Similarly, the levels of mouse leptin from mice treated with PEG-LPrA2 were lower than those from control but no differences were detected in plasma (Figure 4c). In a similar way, PEG-LPrA2 treatment reduced the levels of human leptin within MDA-MB231 BC xenografts but tumor levels of mouse leptin were similar between treated and controls (Figure 4d). In comparison, MDA-MB231 BC lysates from control mice exhibited higher levels of human leptin but lower levels of mouse leptin (Figure 4d) than those from control mice hosting MCF-7 BC xenografts (Figure 4c). Immunoprecipitation/western blot analysis revealed a notable reduction of human OB-Rb expression in MCF-7 and MDA-MB231 BC xenografts in mice treated with PEG-LPrA2 compared with controls (Figure 4c,d).
###end p 55
###begin title 56
General effects of PEG-LPrA2
###end title 56
###begin p 57
###xml 326 327 326 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 395 399 <span type="species:ncbi:10090">mice</span>
###xml 785 789 <span type="species:ncbi:10090">mice</span>
Overall, PEG-LPrA2 was not toxic and did not affect the energy balance (body weight, carcass weight or food intake) of treated mice when compared with control mice hosting MCF-7 or MDA-MB231 BC xenografts. Significant differences were found, however, between carcass weights from mice hosting MCF-7 BC and MDA-MB231 BC (Table 1). An increased amount of abdominal fat was found in ovariectomized mice hosting MCF-7 BC xenografts compared with those hosting MDA-MB231 BC xenografts. These differences were found not related to PEG-LPrA2 or control treatments. PEG-LPrA2 delayed tumor onset and growth, and negatively impacted on the levels of pro-angiogenic, pro-inflammatory and pro-proliferative molecules in both types of BC. There were more notable effects of PEG-LPrA2, however, in mice hosting MCF-7-derived BC xenografts.
###end p 57
###begin p 58
###xml 21 26 <span type="species:ncbi:10090">mouse</span>
Treatment effects on mouse energy balance and growth of MCF-7 and MDA-MB231 breast cancer xenografts
###end p 58
###begin p 59
###xml 93 95 91 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 147 151 <span type="species:ncbi:10090">mice</span>
###xml 324 328 <span type="species:ncbi:10090">mice</span>
Data expressed as mean +/- standard deviation (n = 10 tumors/breast cancer type/treatment). *P < 0.05, significant difference in carcass weight of mice hosting MDA-MB-231 breast cancer xenografts treated with pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) or pegylated scrambled peptide (Sc-PEG) with respect to mice hosting MCF-7 breast cancer xenografts (n = 10 tumors/treatment).
###end p 59
###begin title 60
Leptin receptor and estrogen receptor in cancer cell cultures
###end title 60
###begin p 61
MCF-7 and MDA-MB231 cells expressed OB-R, but only MCF-7 cells expressed ERalpha (immunocytochemistry and western blot; data not shown).
###end p 61
###begin title 62
Leptin in cancer cell cultures
###end title 62
###begin p 63
MDA-MB231 cells (9.6 pg/ml/mg, equivalent to 0.41 pM) under basal conditions secreted more leptin (approximately fourfold) than MCF-7 cells (2.6 pg/ml/mg, equivalent to 0.15 pM).
###end p 63
###begin title 64
VEGF and VEGFR2 in cancer cell cultures
###end title 64
###begin p 65
###xml 73 75 73 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5a</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5b</xref>
###xml 904 908 904 908 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c,d</xref>
###xml 1019 1023 1019 1023 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5c,d</xref>
Basal secretion of VEGF was much higher from MDA-MB231 (~46-fold; Figure 5b) than from MCF-7 (Figure 5a) cell cultures. Leptin significantly increased the levels of VEGF in medium of MCF-7 cell cultures at all the leptin doses assayed (Figure 5a) but had no effects on VEGF levels in MDA-MB231 cell cultures (Figure 5b). Importantly, the co-incubation of MCF-7 cells with leptin and PEG-LPrA2 completely abrogated the leptin-mediated increase in VEGF in the conditioned medium (Figure 5a). Real-time RT-PCR analysis indicated that leptin upregulates the transcriptional expression of VEGF in MCF-7 cells (Figure 5a) and in MDA-MB231 cells (Figure 5b). The co-incubation of cells with leptin and PEG-LPrA2 inhibited the leptin effects on VEGF mRNA levels. In both types of cells, leptin in a dose-response manner significantly increased the levels of VEGFR2, and PEG-LPrA2 abrogated these effects (Figure 5c,d). Real-time RT-PCR showed that leptin also increased the expression of VEGFR2 mRNA in both cell types (Figure 5c,d) that were inhibited by PEG-LPrA2.
###end p 65
###begin p 66
###xml 260 263 260 263 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a,c</bold>
###xml 289 292 289 292 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b,d</bold>
###xml 928 930 924 926 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Leptin effects on VEGF and VEGFR2 protein and mRNA in MCF-7 and MDA-MB231 cultures. Vascular endothelial growth factor (VEGF) protein and mRNA and vascular endothelial growth factor receptor type 2 (VEGFR2) protein and mRNA levels in MCF-7 breast cancer (BC) (a,c) and MDA-MB231 BC cells (b,d), respectively. The cells were cultured for 48 hours in medium containing leptin (0 to 6.25 nM, equivalent to 10 to 100 ng/ml) and/or pegylated leptin peptide receptor antagonist 2 (PEG-LPrA2) (3 muM). Levels of VEGF protein in the supernatants determined by ELISA. Levels of VEGFR2 protein in cell lysates determined by immunoprecipitation/western blot. beta-Actin used as loading control for western blot determinations. VEGF and VEGFR2 mRNA determined by real-time RT-PCR and expressed as relative values to basal conditions. All data were derived from a minimum of three independent experiments using different cell preparations. *P < 0.05, comparing levels of basal cells with treated cells.
###end p 66
###begin title 67
Discussion
###end title 67
###begin p 68
###xml 107 109 107 109 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 149 151 149 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 1085 1086 1085 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 1105 1106 1105 1106 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 169 173 <span type="species:ncbi:10090">mice</span>
###xml 527 532 <span type="species:ncbi:10090">mouse</span>
###xml 560 565 <span type="species:ncbi:9606">human</span>
###xml 757 764 <span type="species:ncbi:9606">patient</span>
###xml 816 821 <span type="species:ncbi:9606">human</span>
###xml 886 891 <span type="species:ncbi:9606">human</span>
###xml 911 915 <span type="species:ncbi:10090">mice</span>
The present investigation outlines for the first time the contributions of leptin to the growth of human ER+ BC xenografts and the very aggressive ER- BC hosted by SCID mice. A potent antagonist for the leptin receptor, PEG-LPrA2 (with an extended half-life of 60 hours), was used to test the impact of leptin signaling inhibition on the growth of BC and the expression of leptin-targeted molecules important for BC angiogenesis and proliferation. It is well known that while there are significant strengths in the use of this mouse model that does not reject human BC cells, there also are limitations - including the lack of the physiological immune reaction to the disturbance of leptin's inflammatory functions that may influence the prediction of a BC patient's response to this therapy. To have an idea of how human BC could respond to PEG-LPrA2, however, it was necessary to use human BC growing in SCID mice. The significance of leptin-induced signaling in the regulation of VEGF and VEGFR2 expression (at protein and mRNA levels) was also investigated in cultures of MCF-7 (ER+) and MDA-MB231 (ER-) BC cells.
###end p 68
###begin p 69
###xml 172 174 172 174 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 180 182 180 182 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 191 200 191 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 411 413 411 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 469 471 469 471 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 483 485 483 485 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 454 458 <span type="species:ncbi:10090">mice</span>
The data presented support the potential translational use of PEG-LPrA2 for prevention and/or treatment of BC. Differential effects for leptin signaling on the growth of ER+ and ER- BC cells in vitro have been reported [36,37]. These effects could be related to leptin-induced levels of aromatase [17,18] and to ER transactivation [19]. Leptin was therefore expected to have stronger effects on the growth of ER+ BC. To investigate this hypothesis, SCID mice hosting ER+ MCF-7 and ER- MDA-MB231 BC xenografts were treated with a leptin-signaling antagonist, PEG-LPrA2.
###end p 69
###begin p 70
###xml 39 41 39 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 47 49 47 49 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 124 129 <span type="species:ncbi:9606">human</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 546 550 <span type="species:ncbi:10090">mice</span>
An impressive reduction of growth of ER+ and ER- BC xenografts was found after PEG-LPrA2 treatment. Moreover, both types of human BC xenografts responded to PEG-LPrA2 treatment by reducing the expression of several leptin-targeted molecules. Different growth rates for MCF-7 BC and MDA-MB231 BC xenografts in control mice (receiving Sc-PEG) were detected after 14 days of treatment. Although the exact reasons for this finding are unknown, it could be related to the boost of estradiol after re-emplacing the estradiol capsules in ovariectomized mice hosting MCF-7 BC.
###end p 70
###begin p 71
###xml 816 821 <span type="species:ncbi:9606">human</span>
###xml 856 860 <span type="species:ncbi:10090">mice</span>
###xml 1017 1022 <span type="species:ncbi:9606">human</span>
###xml 1060 1064 <span type="species:ncbi:10090">mice</span>
###xml 1370 1375 <span type="species:ncbi:10090">mouse</span>
The present data further support the idea that leptin signaling plays an important role in BC development and/or progression that may be mechanistically linked to leptin-mediated upregulation of pro-angiogenic and pro-proliferative factors. Inhibition of leptin signaling, however, more markedly reduced the growth and expression of leptin-related molecules in MCF-7 BC in comparison with MDA-MB231 BC xenografts. Specifically, leptin signaling inhibition decreased the levels of VEGF and leptin and their respective receptors within both BC xenograft types. MDA-MB231 BC xenografts had higher levels of VEGF and leptin than MCF-7 BC xenografts. The inhibition of leptin signaling therefore almost completely blocked VEGF expression and reduced leptin levels within MCF-7 BC. Reasons for the relative high levels of human leptin found in plasma of treated mice hosting MCF-7 are unknown but could be related to cross-reactivity of ELISA antibodies with leptin peptide receptor antagonist 2 (composed by a stretch the human leptin molecule). The ovariectomized mice hosting MCF-7 showed higher accumulation of abdominal fat than those nonovariectomized hosting MDA-MB231 BC cells. PEG-LPrA2 has an enhanced half-life (60 hours) compared with leptin (approximately 1 hour). Preliminary pharmacokinetics studies showed that PEG-LPrA2 was found at a higher concentration in mouse adipose tissue (RR Gonzalez, unpublished data).
###end p 71
###begin p 72
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 60 62 60 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 236 237 236 237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 497 498 494 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 509 511 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 512 514 509 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 515 517 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 540 542 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 672 674 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 675 677 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 678 680 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 681 683 678 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 989 991 986 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1135 1136 1132 1133 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 187 192 <span type="species:ncbi:10090">mouse</span>
###xml 204 209 <span type="species:ncbi:9606">human</span>
###xml 1024 1028 <span type="species:ncbi:10090">mice</span>
Leptin is an upstream regulator of angiogenic molecules [21,24,32,33,38-40]. Leptin peptide receptor antagonist 2 treatment decreased the levels of leptin-induced angiogenic molecules in mouse tumors and human endometrial cancer cells [3,24]. These data suggest that the inhibition of leptin signaling negatively impacted tumor growth by decreasing leptin-induced expression of several factors implicated in epithelial cell proliferation, adhesion, inflammation and angiogenesis; for example, beta3-integrin [38,41,42], metalloproteinases [43], leukemia inhibitory factor, leukemia inhibitory factor receptor, IL-1, IL-1 receptor (IL-1R tI), and IL-1 receptor antagonist [32,34,38-40]. Many genes regulated by leptin in MCF-7 cells are related to growth factors, cell cycle regulators, extracellular matrix, metastasis (that is, cyclin D, cyclin G, cyclin-dependent kinase 2, p21, p27, p16, connective tissue growth factor, villin 2, and basigin), and anti-apoptosis (BCL2 and surviving) [28]. In line with this notion, the mice treated with PEG-LPrA2 had diminished expression of VEGF/VEGFR2, OB-R, leptin, IL-1R tI, PCNA and cyclin D1.
###end p 72
###begin p 73
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 191 193 191 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 241 243 241 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 252 254 252 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Even though normal mammary cells express leptin and OB-R, abnormal high levels of leptin/OB-R expression are found in BC that is related to both the metastasis and lower survival rates [1,11,13]. The reduction of leptin and OB-R levels in ER- BC and ER+ BC after PEG-LPrA2 treatment could therefore negatively impact on leptin's actions within BC and may have a potential value as subrogate markers to assess the efficacy of leptin-signaling inhibition as a novel anticancer therapy.
###end p 73
###begin p 74
###xml 148 150 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 650 652 650 652 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 987 989 987 989 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1104 1105 1104 1105 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 262 267 <span type="species:ncbi:10090">mouse</span>
###xml 387 392 <span type="species:ncbi:10090">mouse</span>
###xml 518 523 <span type="species:ncbi:9606">human</span>
###xml 944 949 <span type="species:ncbi:9606">human</span>
###xml 954 959 <span type="species:ncbi:10090">mouse</span>
###xml 1155 1160 <span type="species:ncbi:10090">mouse</span>
###xml 1354 1358 <span type="species:ncbi:10090">mice</span>
It is known that tumor stroma (noncancerous cells; that is, fibroblasts, immune and endothelial cells) could play a role in promoting tumor growth [44]. To gain further insight into mechanisms of leptin-induced tumor growth and angiogenesis in BC, the levels of mouse VEGF and leptin in tumor stroma were investigated. Interestingly, stroma from MCF-7 BC xenografts had higher levels of mouse VEGF and leptin than those found in stroma from MDA-MB231 BC xenografts. These data were in contrast to the higher levels of human VEGF secreted by MDA-MB231 BC in comparison with VEGF levels secreted by MCF-7 BC xenografts. These data suggest that MCF-7 ER+ BC differentially secrete factors inducing the expression of VEGF and leptin by tumor stroma compared with MDA-MB231 BC. Factors secreted by MCF-7 BC could further promote via tumor-stroma angiogenesis and, consequently, tumor growth [44]. Remarkably, PEG-LPrA2 treatment decreased levels of human and mouse VEGF and leptin in MCF-7 ER+ BC. This could explain in part the higher effectiveness of PEG-LPrA2 treatment in reducing tumor growth in MCF-7 ER+. Importantly, PEG-LPrA2 treatment did not affect mouse leptin levels in plasma, suggesting that this compound did not interfere with the systemic leptin metabolism. Indeed, no significant effects on body weight or carcass weight were found between mice hosting the same type of BC xenografts and treated with PEG-LPrA2 or Sc-PEG control.
###end p 74
###begin p 75
###xml 122 130 122 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro</italic>
###xml 643 652 643 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
The role of leptin signaling in the regulation of VEGF and VEGFR2 by MCF-7 and MDA-MB231 cancer cells was further studied in vitro. Leptin and VEGF basal levels were higher in MDA-MB231 compared with those from MCF-7 cells, but leptin increased the levels of secreted protein VEGF only in MCF-7 cells. In contrast, VEGF mRNA expression was upregulated by leptin in both cell types. This is probably due to the constitutive expression of VEGF and/or the autocrine and paracrine actions of leptin in MDA-MB231 cells. Remarkably, leptin-induced effects on VEGF and VEGFR2 levels were abrogated by co-incubation of cells with PEG-LPrA2. Data from in vitro studies correlate with findings from BC xenografts. These data further suggest that leptin could induce VEGF/VEGFR2 expression in BC.
###end p 75
###begin p 76
###xml 230 232 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 251 253 251 253 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 624 626 624 626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 679 682 679 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu</italic>
###xml 692 694 692 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">neu </italic>
###xml 764 766 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 893 895 893 895 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 896 898 896 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 967 969 967 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1068 1070 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1106 1108 1106 1108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 632 637 <span type="species:ncbi:9606">human</span>
###xml 1453 1458 <span type="species:ncbi:9606">human</span>
Taken together, the present data support a role for leptin as a tumor growth factor. Moreover, the leptin effect is probably mediated via several angiogenic and pro-proliferative molecules in BC. The increased susceptibility of ER+ BC compared with ER- BC to the negative impact of PEG-LPrA2 leptin-signaling inhibition could partially be related to differential mechanisms for leptin regulation of VEGF/VEGFR2 in the BC cells used. In addition, it cannot be ruled out that leptin-signaling crosstalk could activate other signaling mechanisms related to essential factors for BC growth; that is, insulin-like growth factor [45] and human epidermal growth factor receptor-2 (HER2/neu; erbB2) [46]. HER2/neu increases the levels of the anti-apoptotic protein Bcl-2 [47] and pro-proliferative molecules, the cyclin-dependent kinase inhibitor p27Kip1 and the cell cycle regulatory protein cyclin D1 [48]. HER2/neu shows moderate to low expression by MCF-7 and MDA-MB231 [46], but the HER2/neu-leptin signaling link can further increase the levels of pro-survival factors [26,27] and pro-proliferative factors [24]. Off-target effects of PEG-LPrA2 treatment therefore cannot be excluded from the interpretation of data. Nevertheless, these data suggest that targeting leptin/OB-R functions may negatively impact tumor growth, angiogenesis, apoptosis, and expression of inflammation-related factors and could impair leptin-growth promoter-factor crosstalk in human BC.
###end p 76
###begin p 77
###xml 274 275 274 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 391 393 391 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 774 778 <span type="species:ncbi:10090">mice</span>
###xml 951 955 <span type="species:ncbi:10090">mice</span>
###xml 965 969 <span type="species:ncbi:10090">mice</span>
Our present findings may have particular importance for designing new therapies for BC and other cancer types (that is, endometrial cancer, colon cancer, prostate cancer, and so forth) where obesity and leptin signaling have also been related to their incidence and growth [8,23]. Inhibition of leptin signaling could be especially useful for the treatment of more aggressive and invasive ER- BC that is currently treated with a variety of chemotherapeutics with many debilitating side effects [20]. In contrast, preliminary pharmacokinetic and toxicological studies suggest that the high-molecular-weight PEG-LPrA2 derivative does not travel through the blood-brain barrier and therefore it is not bound to hypothalamic OB-R or accumulated in the central nervous system of mice. This suggests PEG-LPrA2 may not interfere with leptin biological actions at the hypothalamic level. PEG-LPrA2 shows no detrimental effects on the general health status of mice. Indeed, mice treated for more than 2 months with PEG-LPrA2 showed no evident toxicity or change in appetite/energy balance, insulin/glucose levels, or general health status (RR Gonzalez, unpublished data).
###end p 77
###begin title 78
Conclusions
###end title 78
###begin p 79
###xml 159 161 159 161 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 173 175 173 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 376 378 376 378 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 471 473 471 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 907 909 907 909 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 918 920 918 920 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 151 156 <span type="species:ncbi:9606">human</span>
###xml 737 742 <span type="species:ncbi:9606">women</span>
Results from the present investigation strongly support the idea that leptin signaling plays an important role in the establishment and growth of both human ER+ MCF-7 and ER- MDA-MB231 BC xenografts. Leptin actions in these tumors are probably related to leptin-mediated increase in levels of VEGF/VEGFR2 and OB-R and other leptin-targeted molecules essential to BC growth. ER+ BC was more responsive, however, to PEG-LPrA2 mediated inhibition of leptin signaling than ER- BC. Overall, our data open the possibility that inhibition of leptin signaling may serve as a novel adjuvant for prevention and treatment of BC, particularly in populations under higher risk and exhibiting higher levels of leptin: such as obese and postmenopausal women. The alarming increase of incidence of obesity in the western countries emphasizes the importance of our findings on leptin-signaling inhibition for reduction of ER+ BC and ER- BC growth.
###end p 79
###begin title 80
Abbreviations
###end title 80
###begin p 81
###xml 40 46 <span type="species:ncbi:9913">bovine</span>
BC: breast cancer; bp: base pairs; BSA: bovine serum albumin; ELISA: enzyme-linked immunosorbent assay; ER: estrogen receptor; IL: interleukin-1; IL-1R tI: interleukin-1 receptor type I; MT: mammary tumor; OB-R: leptin receptor; PBS: phosphate-buffered saline; PCNA: proliferating cell nuclear antigen; PEG-LPrA2: pegylated leptin peptide receptor antagonist 2; SCID: severely compromised immunodeficient; Sc-PEG: pegylated scrambled peptide; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor; VEGFR2: vascular endothelial growth factor receptor type 2 (Flk-1).
###end p 81
###begin title 82
Competing interests
###end title 82
###begin p 83
The authors declare that they have no competing interests. RRG is an inventor of the Boston Biomedical Research Institute's patent Leptin Peptide Antagonists (US Patent 7407929, Application No. 10/841,218; International Application No. PCT/US 05/15198). No financial benefits have been derived from this patent.
###end p 83
###begin title 84
Authors' contributions
###end title 84
###begin p 85
RRG conceived of the study, participated in its design and coordination, and drafted the manuscript. AW participated in the animal trials, and helped carry out the immunohistochemical studies and western blot and ELISA determinations of relevant molecules. YX carried out the molecular genetic studies. UPS participated in the immunohistochemical studies. DRM participated in drafting the manuscript. BRR participated in the design of the study and drafted the manuscript. MLP participated in the design of the study and drafted the manuscript. All authors read and approved the final manuscript.
###end p 85
###begin title 86
Acknowledgements
###end title 86
###begin p 87
The authors thank Dr Tracy R Daniels, University of California, Los Angeles, CA, USA for her useful suggestions, Dr Fang Tan, Emory University School of Medicine, Atlanta, GA, USA for the donation of primers for VEGF and VEGFR2, and Dr Alexander Quarshie, Director Biostatistics and Data Management Core, Associate Director, Master of Science in Clinical Research Program, Morehouse School of Medicine for his help with the statistical analysis.
###end p 87
###begin p 88
Funding awarded to RRG includes NIH/NCI 5SC1CA138658-01, NIH/UAB Breast SPORE Career Development Award, BC 504370 Susan G. Komen Foundation for the Cure, the Cancer Research and Prevention Foundation, the Georgia Cancer Coalition Distinguished Cancer Scholar Award, CIG-07-114 Consortium for Industrial Collaboration in Contraceptive Research (CICCR), and Contraceptive Research and Development Program (CONRAD), Eastern Virginia Medical School. Funding awarded to DRM includes NIH/HD41749. Other funds were from the Morehouse School of Medicine Dean's Fund for Minority Student Training, facilities and support services at Morehouse School of Medicine (NIH RR03034 and 1C06 RR18386).
###end p 88
###begin article-title 89
###xml 60 65 <span type="species:ncbi:9606">human</span>
Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer
###end article-title 89
###begin article-title 90
Aberrant expression and possible involvement of the leptin receptor in endometrial cancer
###end article-title 90
###begin article-title 91
Leptin regulation of pro-angiogenic molecules in benign and cancer endometrial cells
###end article-title 91
###begin article-title 92
The leptin receptor
###end article-title 92
###begin article-title 93
The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors
###end article-title 93
###begin article-title 94
Obesity and cancer
###end article-title 94
###begin article-title 95
The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer
###end article-title 95
###begin article-title 96
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults
###end article-title 96
###begin article-title 97
Leptin and cancer
###end article-title 97
###begin article-title 98
Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression
###end article-title 98
###begin article-title 99
Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls
###end article-title 99
###begin article-title 100
Leptin and insulin growth factor I in relation to breast cancer (Greece)
###end article-title 100
###begin article-title 101
###xml 92 100 <span type="species:ncbi:9606">patients</span>
High expression of leptin receptor mRNA in breast cancer tissue predicts poor prognosis for patients with high, but not low, serum leptin levels
###end article-title 101
###begin article-title 102
Leptin - a growth factor in normal and malignant breast cells and for normal mammary gland development
###end article-title 102
###begin article-title 103
###xml 155 163 <span type="species:ncbi:9606">patients</span>
Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients. Toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions
###end article-title 103
###begin article-title 104
The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm
###end article-title 104
###begin article-title 105
###xml 44 49 <span type="species:ncbi:9606">human</span>
Leptin mediates a proliferative response in human MCF-7 breast cancer cells
###end article-title 105
###begin article-title 106
Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line
###end article-title 106
###begin article-title 107
Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells
###end article-title 107
###begin article-title 108
Side effects of adjuvant treatment of breast cancer
###end article-title 108
###begin article-title 109
Biological action of leptin as an angiogenic factor
###end article-title 109
###begin article-title 110
###xml 62 67 <span type="species:ncbi:9606">human</span>
Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression
###end article-title 110
###begin article-title 111
###xml 103 105 103 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 25 30 <span type="species:ncbi:9606">human</span>
Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21WAF1/CIP1
###end article-title 111
###begin article-title 112
Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2)
###end article-title 112
###begin article-title 113
Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF-7 breast cancer cells
###end article-title 113
###begin article-title 114
Leptin inhibits stress-induced apoptosis of T lymphocytes
###end article-title 114
###begin article-title 115
Protection against lipoapoptosis of beta cells through leptin-dependent maintenance of Bcl-2 expression
###end article-title 115
###begin article-title 116
Leptin-regulated gene expression in MCF-7 breast cancer cells: mechanistic insights into leptin-regulated mammary tumor growth and progression
###end article-title 116
###begin article-title 117
###xml 68 72 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 83 87 <span type="species:ncbi:10090">mice</span>
Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice
###end article-title 117
###begin article-title 118
###xml 18 22 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 55 59 <span type="species:ncbi:10090">mice</span>
Genetically obese MMTV-TGF-alpha/Lep(ob)Lep(ob) female mice do not develop mammary tumors
###end article-title 118
###begin article-title 119
###xml 26 30 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Leptin receptor-deficient MMTV-TGF-alpha/Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors
###end article-title 119
###begin article-title 120
###xml 27 32 <span type="species:ncbi:9606">human</span>
###xml 106 112 <span type="species:ncbi:9986">rabbit</span>
A peptide derived from the human leptin molecule is a potent inhibitor of the leptin receptor function in rabbit endometrial cells
###end article-title 120
###begin article-title 121
NIH Image Program
###end article-title 121
###begin article-title 122
Leptin serves as an upstream activator of an obligatory signaling cascade in the embryo-implantation process
###end article-title 122
###begin article-title 123
Analyse-it for Microsoft Excel
###end article-title 123
###begin article-title 124
###xml 21 26 <span type="species:ncbi:9606">human</span>
Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status
###end article-title 124
###begin article-title 125
###xml 103 108 <span type="species:ncbi:9606">human</span>
A novel unidirectional cross-talk from the insulin-like growth factor-I receptor to leptin receptor in human breast cancer cells
###end article-title 125
###begin article-title 126
###xml 74 79 <span type="species:ncbi:9606">human</span>
Leptin-induced increase in leukemia inhibitory factor and its receptor by human endometrium is partially mediated by interleukin 1 receptor signaling
###end article-title 126
###begin article-title 127
###xml 123 129 <span type="species:ncbi:10090">murine</span>
Ablation of leptin signaling disrupts the establishment, development of and maintenance of endometriosis-like lesions in a murine model
###end article-title 127
###begin article-title 128
###xml 49 54 <span type="species:ncbi:9606">human</span>
Leptin regulation of the interleukin-1 system in human endometrial cells
###end article-title 128
###begin article-title 129
###xml 25 26 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 114 119 <span type="species:ncbi:9606">human</span>
Leptin up-regulates beta 3-integrin expression and IL-1beta up-regulates leptin and leptin receptor expression in human endometrial epithelial cell cultures
###end article-title 129
###begin article-title 130
###xml 34 39 <span type="species:ncbi:9606">human</span>
Leptin enhances cell migration in human chondrosarcoma cells through OBRl leptin receptor
###end article-title 130
###begin article-title 131
Effects of leptin, interleukin-1alpha, interleukin-6, and transforming growth factor-beta on markers of trophoblast invasive phenotype: integrins and metalloproteinases
###end article-title 131
###begin article-title 132
Targeting the stroma by T cells to limit tumor growth
###end article-title 132
###begin article-title 133
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor
###end article-title 133
###begin article-title 134
Transactivation of erbB2 by short and long isoforms of leptin receptors
###end article-title 134
###begin article-title 135
Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene-amplified breast cancer cells
###end article-title 135
###begin article-title 136
###xml 56 58 56 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
ErbB2/neu kinase modulates cellular p27Kip1 and cyclin D1 through multiple signaling pathways
###end article-title 136

